Cassava Sciences Announces Expansion of Leadership Team
October 27 2022 - 9:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, announced the
expansion of its leadership team with the appointment of
Christopher Cook as Senior Vice President and General Counsel. This
is a newly created position, reporting to Remi Barbier, President
& CEO.
“Chris is an accomplished legal advisor, a
skilled litigator and a proven leader in legal matters,” said Remi
Barbier. "We’re very excited that Chris will shortly join us as
Cassava Sciences’ in-house General Counsel. I’m confident his
experience and deep expertise will be a critical addition to the
Company’s business operations and strategic initiatives.”
Chris has over 25 years of experience working in
health care, private practice and government. He joins Cassava
Sciences from Alcon, a publicly traded medical company, where he
served as the Global Head of Litigation and Government
Investigations since 2017. Prior to Alcon, he was the Vice
President and division General Counsel for Walmart Central America
in San Jose, Costa Rica. Chris practiced law at Jones Day, a
multinational law firm, for seventeen years, where he was a
litigation partner in the firm's Washington, DC and Chicago
offices. Before Jones Day, Chris served as an Assistant United
States Attorney in Chicago. He holds a B.A. in English from Emory
University and a Juris Doctor from Harvard Law School.
Phase 3 Clinical Program
Cassava Sciences’ on-going Phase 3 program consists of two
double-blind, randomized, placebo-controlled studies of simufilam,
an investigational oral drug, in approximately 1,750 patients with
mild-to-moderate Alzheimer’s disease. Both Phase 3 studies have
Special Protocol Assessments (SPA) from the U.S. Food and Drug
Administration. For more information about Cassava Sciences’ Phase
3 studies, please visit ClinicalTrials.gov:
https://www.clinicaltrials.gov/ct2/show/NCT04994483?term=simufilam&draw=2&rank=3https://www.clinicaltrials.gov/ct2/show/NCT05026177?term=simufilam&draw=2&rank=4
About SimufilamSimufilam is
Cassava Sciences’ proprietary, small molecule (oral) drug candidate
that restores the normal shape and function of altered filamin A
(FLNA) protein in the brain. Cassava Sciences owns worldwide
development and commercial rights to its research programs in
Alzheimer’s disease, and related technologies, without royalty
obligations to any third party.
About Cassava Sciences,
Inc.Cassava Sciences, Inc. is a clinical-stage
biotechnology company based in Austin, Texas. Our mission is to
detect and treat neurodegenerative diseases, such as Alzheimer’s
disease. Our novel science is based on stabilizing – but not
removing – a critical protein in the brain. For more information,
please visit: https://www.CassavaSciences.com.
For More Information Contact:
Eric Schoen, Chief Financial Officer(512)
501-2450eschoen@CassavaSciences.com
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2023 to Apr 2024